| Schedule of segment reporting information, by segment |
The following table provides information related to our operating segments based upon the Company's net loss for the years ended December 31, 2025 and 2024 (in thousands):
|
Year Ended December 31, |
|
|
2025 |
|
|
2024 |
|
|
Biopharm |
|
|
Neurostimulation |
|
|
|
|
|
Biopharm |
|
|
Neurostimulation |
|
|
|
|
|
Division
|
|
|
Division |
|
|
Total |
|
|
Division |
|
|
Division |
|
|
Total |
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Personnel and related expenses |
$ |
10,275 |
|
|
$ |
1,139 |
|
|
$ |
11,414 |
|
|
$ |
10,053 |
|
|
$ |
1,752 |
|
|
$ |
11,805 |
|
| Office space rental related expenses |
|
4,213 |
|
|
|
319 |
|
|
|
4,532 |
|
|
|
3,999 |
|
|
|
— |
|
|
|
3,999 |
|
| Development expenses |
|
4,329 |
|
|
|
— |
|
|
|
4,329 |
|
|
|
2,765 |
|
|
|
294 |
|
|
|
3,059 |
|
| Professional services and insurance |
|
4,911 |
|
|
|
836 |
|
|
|
5,747 |
|
|
|
4,600 |
|
|
|
— |
|
|
|
4,600 |
|
| Depreciation |
|
411 |
|
|
|
13 |
|
|
|
424 |
|
|
|
378 |
|
|
|
30 |
|
|
|
408 |
|
| Other general and administrative expenses |
|
785 |
|
|
|
325 |
|
|
|
1,110 |
|
|
|
806 |
|
|
|
— |
|
|
|
806 |
|
| Other (income) expense, net |
|
(821 |
) |
|
|
(126 |
) |
|
|
(947 |
) |
|
|
(1,347 |
) |
|
|
156 |
|
|
|
(1,191 |
) |
| Segment net loss |
$ |
24,103 |
|
|
$ |
2,506 |
|
|
$ |
26,609 |
|
|
$ |
21,254 |
|
|
$ |
2,232 |
|
|
$ |
23,486 |
|
|